Argentina Bans Products Containing Retatrutide, Cites Unapproved Clinical Status

Argentina's ANMAT prohibited all human-use products declaring retatrutide, including online offerings, as the substance remains under clinical investigation with no authorized medications in the country. The ban targets unapproved weight-loss products, reflecting regulatory action against an investigational drug. This signals potential supply-chain and enforcement concerns for similar peptides in the region.